By JoelJuly 8, 20264 min read
June was a milestone month for families living with type 1 diabetes (T1D). The U.S. Food and Drug Administration (FDA) made not one, but two important decisions that directly affect children — and if your family is newly navigating a T1D diagnosis, both are worth knowing about.
What Happened?
On June 12, 2026, the FDA cleared the Dexcom Stelo continuous glucose monitor (CGM) for over-the-counter use in children as young as 2 years old — the first OTC CGM ever cleared for a pediatric population. On that same day, the FDA also granted accelerated approval to teplizumab (Tzield; Sanofi) for a new indication: slowing the loss of insulin production in children and adolescents aged 8 to 17 who were recently diagnosed with Stage 3 Type 1 diabetes.
Two separate tools. Two different problems. Both aimed squarely at helping kids and their families.
The Over-the-Counter CGM: Glucose Tracking Without a Prescription
A continuous glucose monitor (CGM) is a small wearable sensor — usually placed on the arm — that tracks your child's blood sugar around the clock, so you don't have to rely only on finger-stick tests. Until now, getting one for your child required a doctor's prescription.
The FDA has cleared Dexcom's Stelo Glucose Biosensor System as the first over-the-counter continuous (OTC) glucose monitor for children aged two and older who do not use insulin. This includes children with diabetes who manage their condition with oral medications, as well as families interested in seeing how factors like diet and exercise affect glucose levels.
Stelo pairs a wearable sensor with a smartphone app that displays glucose measurements and trends every 15 minutes. For parents, that means a near-real-time window into how your child's body is responding to meals, activity, and stress — no waiting, no guessing.
One important note: This OTC clearance is for children not currently on insulin. Children with Type 1 diabetes using insulin will continue to use prescription-level CGMs (like the Dexcom G7) that integrate with insulin pumps and have more intensive monitoring features. Still, for families in the early monitoring stages, or for siblings at risk of T1D, this could be a game-changer in accessibility.
Tzield for Newly Diagnosed Kids: Protecting What's Left
When a child is first diagnosed with T1D, their body still has some insulin-producing beta cells left — they're just under attack from the immune system. A drug called teplizumab (Tzield) works by calming that immune attack, giving those remaining cells a fighting chance.
On June 12, 2026, the U.S. Food and Drug Administration granted accelerated approval to Tzield (teplizumab) for a new indication, to delay the decline of insulin production in pediatric patients ages 8 through 17 years who have been recently diagnosed.
Why does preserving insulin production matter? The more of their own insulin your child can still make, even in small amounts, the easier blood sugar management tends to be. It can mean fewer dangerous highs and lows, and potentially a longer "honeymoon period" after diagnosis where control is more stable.
What This Means for Your Family
These two developments address different stages and aspects of the same disease — one making it easier for families to track glucose, and the other targeting the underlying disease process itself.
If your child was recently diagnosed, here's a simple takeaway:
- Ask your endocrinologist about Tzield if your child is between 8 and 17 years old and was recently diagnosed. Timing matters — this therapy is designed for the early stage after diagnosis.
- Talk to your care team about CGM options. Even if the OTC Stelo isn't designed for insulin-using kids, your child likely qualifies for a prescription CGM that offers similar (or even more advanced) monitoring.
The pace of progress in T1D care is genuinely accelerating. These announcements are a reminder that researchers, regulators, and companies are working hard on behalf of your child. You're not navigating this alone — and the tools available to your family today are better than they've ever been.
As always, talk to your child's diabetes care team before making any changes to their treatment plan.